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Glutathione S-transferase alpha 4 (GSTA4) is a phase II detoxifying enzyme that is
overexpressed in colorectal cancer (CRC) and regulated by the oncogenic transcription
factor AP-1. However, the role of GSTA4 in these CRC cells remains unclear. In this study,
we investigated the roles of GSTA4 in the CRC cells by inactivating GSTA4 in HCT116
human CRC cells (Deﬁned as HCT116DGSTA4) using the CRISPR/Cas9 gene editing. Cell
proliferation, clonogenicity, and susceptibility to chemotherapeutic drugs were analyzed in
vitro and in a xenograft model. The results showed that loss of GSTA4 signiﬁcantly
decreased cell proliferation and clonogenicity, whereas it increased intracellular reactive
oxygen species and cell susceptibility to 5-ﬂuorouracil (5-FU) and oxaliplatin. Additionally,
exposure of HCT116DGSTA4 cells to 5-FU increased the expression of gH2AX, a hallmark of
double-stranded DNA breaks. In contrast, no remarkably increased gH2AX was noted in
oxaliplatin-treated HCT116DGSTA4 cells compared with HCT116 cells. Moreover, loss of
GSTA4 blocked the AKT and p38 MAPK pathways, leading to proliferative suppression.
Finally, the xenograft model showed decreased tumor size for HCT116DGSTA4 cells
compared with HCT116 cells, conﬁrming in vitro ﬁndings. These ﬁndings suggest that
GSTA4 is capable of promoting proliferation, tumorigenesis, and chemoresistance and is
a potential target for CRC therapy.
Keywords: glutathione S-transferase alpha 4, colorectal cancer, proliferation, reactive oxygen species, chemoresistance

INTRODUCTION
Glutathione S-transferases (GSTs) are phase II detoxifying enzymes that are responsible for
detoxifying xenobiotics and endogenous metabolites of oxidative stress (1). GSTs are also
involved in cell signal transduction, post-translational modiﬁcation, and resistance to
chemotherapeutic drugs (2). In humans, at least 7 classes of GST exist prominently in the
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occurs during mid-treatment, which can signiﬁcantly reduce
survival beneﬁts for CRC patients. Multiple mechanisms and
many signaling molecules are involved in the development of
chemoresistance against 5-FU and oxaliplatin. Of these,
xenobiotic metabolizing enzymes such as GSTs, are important
contributors to chemoresistance (20, 21). Overexpression of
GSTA4 and GSTP1 is associated with the development of
cisplatin resistance in human cancer cells of erythroleukemia,
mammary, and ovary adenocarcinomas (22). Recent studies have
shown that GSTA4 can reduce cisplatin-induced ototoxicity (23).
Whether or not overexpression of GSTA4 contributes to
chemoresistance in CRC is still unknown.
In this study, we inactivated GSTA4 in HCT116 human colon
cancer cells and investigated the effect of GSTA4 on cancer cell
proliferation and chemoresistance. We found that the
inactivation of GSTA4 decreased cell proliferation and
increased intracellular ROS. Additionally, the inactivation of
GSTA4 signiﬁcantly increased the susceptibility of HCT116
cells to the chemotherapeutic drugs 5-FU and oxaliplatin.
Furthermore, inactivation of GSTA4 blocked the AKT and p38
MAPK pathways that are responsible for proliferative
suppression. Finally, inactivation of GSTA4 inhibited xenograft
tumor growth and increased susceptibility to 5-FU and
oxaliplatin in vivo. These ﬁndings demonstrate that
overexpression of GSTA4 promotes CRC cell proliferation,
tumorigenesis, and chemoresistance, indicating that GST A4
blockade may lead to clinical beneﬁts in CRC therapy.

cytosol and, for certain classes, may be found in the
mitochondria or membrane (3). Accumulating evidence has
demonstrated that GSTs are associated with human cancers.
Several classes of GSTs are highly expressed in human cancers,
including colon, kidney, pancreatic, and liver cancers, implying
cancer-promoting effects (4–7). Overexpression of GSTs can
protect cancer cells against oxidative stress and/or promote cell
proliferation through interactions with many growth-promoting
molecules. For example, in a xenograft tumor model, deletion of
GSTP1 signiﬁcantly decreased tumor size via blocking the
mitogen-activated protein kinase (MAPK) signaling pathway
(8). This same GSTP1, on the other hand, can be a tumor
suppressor in the ApcMin/+ mouse model, in which the deletion
of GSTP1 results in increased colon cancer incidence and tumor
multiplicity (9). Additionally, epigenetic down-regulation of
GSTP1 expression has been associated with increased
susceptibility to prostate cancer (10, 11).
The human alpha class GST consists of 5 isozymes that are
responsible for detoxifying a broad range of xenobiotics, namely,
carcinogens, mutagens, chemotherapeutic drugs, steroids, and
byproducts of oxidative stress (12). Some class A GSTs may also
be associated with human cancers as tumor suppressors or tumor
promoters. Recent studies have found that GSTA1 can suppress
hepatocellular carcinoma progression and overexpression of
GSTA1 is correlated with a better prognosis for patients (13).
In contrast, GSTA2 promotes recurrence of hepatocellular
carcinoma by regulating reactive oxygen species (ROS)associated JNK and AKT signaling pathways (5). GSTA4 is a
class A isoenzyme that can speciﬁcally detoxify 4hydroxynonenal (4-HNE), a lipid peroxidation product of w-6
polyunsaturated fatty acid. Single-nucleotide polymorphisms of
the GSTA4 gene are associated with an increased risk of human
nonmelanoma skin cancer, and inactivation of Gsta4 increases
susceptibility to skin cancer in a murine model (14). Previous
studies by our group have shown that GSTA4 is overexpressed in
the biopsies of adenomas and invasive carcinomas from human
beings and murine models (6). However, little is known whether
this highly expressed GSTA4 contributes to the progression and/
or chemoresistance of colorectal cancer (CRC).
Adjuvant chemotherapy has signiﬁcant survival beneﬁts for
patients with late-stage CRC. However, chemoresistance often
occurs during chemotherapy, leading to treatment failure (15,
16). Chemoresistance may be caused by decreased drug inﬂux,
increased drug efﬂux, and altered signaling pathways involved in
cell proliferation and cell death. GSTs can metabolize
chemotherapeutic drugs leading to chemoresistance. Recent
studies have shown that overexpression of GSTP1 or GSTA1 is
associated with cisplatin resistance in human lung, gastric, and
ovarian cancers (17, 18). In contrast, hypermethylation of the
GSTM1 gene reduces GSTM1 expression, which is associated
with increased gemcitabine susceptibility in pancreatic cancer
(19). 5-ﬂuorouracil (5-FU) and oxaliplatin are two major
chemotherapeutic drugs that are usually used in combination
regimens such as FOLFOX (the combination of 5-FU,
leucovorin, and oxaliplatin) for treating advanced CRC (16).
However, acquired resistance to 5-FU and oxaliplatin often
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MATERIALS AND METHODS
Cell Culture
The HCT116 human colon cancer cell line was purchased from
the National Collection of Authenticated Cell Cultures of China
(Shanghai, China). HCT116 cells were cultured in McCoy’s 5A
medium (Wisent, Nanjing, China) supplemented with 10% fetal
bovine serum (Gibco, Carlsbad, CA), 100 mg/ml streptomycin,
and 100 units/ml penicillin G in 5% CO2 at 37°C and subcultured
by trypsinization when conﬂuent.

Inactivation of the GSTA4 Gene
Inactivation of the GSTA4 gene was carried out using the
lentiCRISPRv2 system (Addgene, MA, USA) (24). Guide RNA
(gRNA) sequences were designed to target the human GSTA4
gene using CRISPRdirect (https://crispr.dbcls.jp) (25). Selected
gRNAs (Supplementary Table S1) were cloned into the
pLentiCRISPRv2 vector and transformed into E. coli Stbl3
competent cells (TransGen Biotech, Beijing, China) as
previously reported (24, 26). The positive transformants were
screened by PCR and plasmids were extracted using a TaKaRa
MiniBEST Plasmid Puriﬁcation Kit (Takara, Dalian, China). To
delete a large fragment in the GSTA4 gene, HCT116 cells were
co-transfected with gRNA66 and gRNA214 (Supplementary
Table S1 and Figure 1) using Lipofectamine 3000 reagent
(Invitrogen, Carlsbad, USA) according to the instructions of
the manufacturer. Transfected cells were screened by 4 µg/ml
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FIGURE 1 | Deletion of GSTA4 using CRISPR/Cas9 gene editing. (A) The schematic diagram of the partial human GSTA4 gene and upstream sequence shows the
positions of gRNAs, primers, and deleted fragments in the GSTA4 gene. (B) PCR photograph shows an 871 bp amplicon for HCT116 cells and negative
ampliﬁcation for HCT116DGSTA4 cells using primers hGSTA4-ND-F and hGSTA4-ND-R (Left lanes). A 1,189 bp fragment, as a control, is ampliﬁed for both HCT116
and HCT116DGSTA4 cells (Right lanes). (C) Inactivation of GSTA4 signiﬁcantly increases 4-HNE-induced cell killing following a 48-hour exposure to various doses of 4HNE. All data represent the mean ± SEM for three independent experiments. *P <0.05; **P <0.01.

Additive Solution at RT for 30 min, and sorted on a DxFLEX
ﬂow cytometer (Beckman Coulter, Suzhou, China). EdU-positive
cells were analyzed using CytExpert software.

puromycin followed by a maintenance concentration of 1 µg/ml
puromycin. Clones surviving at 1 µg/ml puromycin were subcultured in a 24-well plate. DNA was extracted for mutant
screening. Deletion of the GSTA4 gene fragment was detected
by PCR ampliﬁcation using speciﬁc primers (Supplementary
Table S1) followed by Sanger sequencing.

Clonogenic Assay
Cells were seeded into 6‐well plates at a density of 1,000 cells/well
and cultured in 5% CO2 at 37°C for 10 days. The clones were
ﬁxed with methanol and stained with 0.1% crystal violet for
30 min. The number of clones was counted.

Cell Viability
Cell viability was determined using the CCK-8 assay kit
(Beyotime Biotechnology, Shanghai, China). Cells were seeded
in 96-well plates (5 × 103 cells/well) and incubated overnight at
37°C. Following a 48-hour treatment with 5-FU or oxaliplatin,
10 ml of CCK-8 solution was added to each well and incubated at
37°C for 4 h. The absorbance was measured at 450 nm using a
Varioskan LUX microplate reader (Thermo Fisher Scientiﬁc,
MA, USA).

Apoptosis Analysis
Apoptosis was analyzed using an Annexin-V/PI Staining kit
(Vazyme, Nanjing, China) according to the instructions of the
manufacturer. In brief, cells were harvested by trypsinization,
washed with PBS, and counted. Cells (1 × 105) were resuspended
in 100 µl binding buffer and incubated with 5 µl Annexin VFITC and 5 µl propidium iodide (PI) at RT for 10 min. Following
staining, 400 µl binding buffer was added and cells were sorted
on a DxFLEX ﬂow cytometer (Beckman Coulter). The
percentage of total apoptotic cells was calculated.

Cell Proliferation Assay

Cell proliferation was determined using the BeyoClick™ EdU555 kit (Beyotime Biotechnology) according to the instructions
of the manufacturer. Brieﬂy, cells were seeded in 6-well plates at a
density of 2.5 × 105 cells/well and incubated at 37°C overnight.
Cells were treated with 5-FU or oxaliplatin for 48 h
and incubated with 10 mM 5-ethynyl-2′-deoxyuridine (EdU) at
37°C for 2 h. Cells were then harvested by trypsinization, ﬁxed
with 4% paraformaldehyde at room temperature (RT) for
15 min, and permeabilized with 0.3% Triton X-100 in PBS at
RT for 10 min. Cells were washed, stained with 500 ml of Click
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Reactive Oxygen Species Analysis
ROS was detected using a ROS Assay Kit (Beyotime
Biotechnology). Brieﬂy, cells were treated with PBS, 5-FU, and
oxaliplatin, respectively, for 48 h. Following treatment, 2’,7’dichlorodihydroﬂuorescein diacetate (DCFH-DA) was added to
a ﬁnal concentration of 10 mM and incubated at 37°C for 30 min.
Cells were harvested, washed with PBS, and re-seeded into a 96-
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well plate at a density of 2 × 104 cells/well. The ﬂuorescence
intensity was measured at 525 nm using an excitation wavelength
of 488 nm at the Varioskan LUX microplate reader (Thermo
Fisher Scientiﬁc). The intensity of ﬂuorescence was normalized
to the ﬂuorescence intensity of the PBS control.

resulted in a 1,135 bp homozygous deletion across exons 1
and 2 in the GSTA4 gene (Figure 1A). Deletion of this
fragment was conﬁrmed by PCR ampliﬁcation and sequence
analysis (Figure 1B and Supplementary Figure S1). This
GSTA4-deﬁcient clone was named HCT116DGSTA4 and was
used for the subsequent studies. Because GSTA4 is a
detoxifying enzyme for 4-HNE, inactivation of GSTA4 in
HCT116 DGSTA4 was further conﬁrmed by a decreased
detoxifying capability for 4-HNE. The viability of
HCT116DGSTA4 cells signiﬁcantly decreased compared to the
parental HCT116 cells when exposed to various concentrations
of 4-HNE for 48 h (Figure 1C), indicating a reduced 4-HNEdetoxifying ability of HCT116DGSTA4 cells.

Western Blotting
Western blotting was performed as described previously (6).
Cells were lysed using lysis buffer and the concentration was
analyzed by the BCA assay (Beyotime Biotechnology). Wholecell lysates were separated by SDS-PAGE, transferred to a PVDF
membrane (Millipore, Shanghai, China), and blocked with 5%
non-fat dry milk in Tris-buffered saline with 0.1% Tween 20
(TBST). The primary antibodies used in the study included antiAKT (1:1,000, Afﬁnity Biosciences, Changzhou, China), anti-pAKT (1:1,000, Cell Signaling Technology, Shanghai, China),
anti-p38 MAP kinase (1:1,000, Afﬁnity Biosciences), antiphosphorylated p38 (1:1,000, Cell Signaling Technology), and
anti-b-actin (1:2,000, Sangon, Shanghai, China). HRPconjugated species-speciﬁc secondary antibodies were
purchased from Beyotime Biotechnology. Signals were
generated by enhanced chemiluminescence (Biosharp, Hefei,
China) and captured by the Odyssey Fc system (LI-COR
Biosciences, Lincoln, NE).

Inactivation of GSTA4 Reduces Cell
Proliferation
To investigate the effect of GSTA4 inactivation, we ﬁrst
determined the cell proliferation of HCT116DGSTA4 cells and
compared them to the parental HCT116 cells. Inactivation of
GSTA4 signiﬁcantly reduced cell proliferation after culturing for
24, 48, and 72 h compared with HCT116 cells (Figure 2A).
Furthermore, clonogenic assays demonstrated that the size and
number of clones formed by HCT116DGSTA4 cells remarkably
decreased compared with clones formed by HCT116 cells
(Figures 2B, C). Additionally, decreased proliferation of
HCT116DGSTA4 cells was conﬁrmed by the EdU incorporation
assay (Figures 2D, E). The ﬂuorescence-activated cell sorting
(FACS) analysis showed that the proportion of EdU-positive
cells signiﬁcantly decreased for HCT116DGSTA4 cells compared
with HCT116 cells (32.6 ± 2.9% vs. 39.1 ± 4.6%, P <0.05). Finally,
apoptosis was analyzed to determine whether the inactivation of
GSTA4 induced apoptosis. FACS analysis showed that, when
cells left untreated, there were no signiﬁcant differences in the
proportions of the early, late, and total apoptotic cells for
HCT116DGSTA4 cells compared to those of HCT116 cells
(Supplementary Figure S2, Ctrl). These results suggest that
GSTA4 contributes to cancer cell proliferation while having no
effect on apoptosis.

Xenograft Assay
The animal study was approved by the Institutional Animal Care
and Use Committees at Nantong University. Male, 6‐week‐old
speciﬁc pathogen-free BALB/cJGpt-Foxn1nu/Gpt nude mice
were used for tumor xenograft. A total of 30 mice were
randomly and equally divided into six groups, with 5 mice per
group. HCT116 (3 groups) or GSTA4-deﬁcient HCT116
(HCT116DGSTA4) cells (3 groups) were subcutaneously injected
into the ﬂanks of the mice (5 × 106 cells/side) for xenograft tumor
growth. One week after xenografting, mice were intraperitoneally
injected with 5-FU (30 mg/kg), oxaliplatin (3 mg/kg), and saline
as control, once a week for 4 weeks. Mouse body weight was
recorded and tumor size was measured weekly. The tumor size
was calculated as described previously (27). Mice were
euthanized after 4-week treatment and tumors were removed
for measuring size, weighing, and histology.

Inactivation of GSTA4 Increases Response
to Chemotherapeutic Agents
GSTs, as phase II detoxifying enzymes, are associated with anticancer drug resistance (28). To investigate whether GSTA4 is
involved in chemoresistance, we determined cell survival rates
for HCT116 and HCT116DGSTA4 cells after exposure to 5-FU and
oxaliplatin, two ﬁrst-line chemotherapeutic agents for colorectal
cancer. As shown in Figure 3, the survival rates signiﬁcantly
decreased for HCT116DGSTA4 cells compared with HCT116 cells
following treatment with 5-FU at the doses of 5, 15, and 30 mM
for 48 h. Similarly, signiﬁcantly decreased survival rates were also
noted for HCT116DGSTA4 cells exposed to oxaliplatin at the doses
of 0.5 and 5 µM for 48 h. Notably, we were unable to ﬁnd
signiﬁcantly increased proportions of early, late, and total
apoptosis in HCT116 cells exposed to 5-FU (5 mM) and
oxaliplatin (5 mM) compared with untreated controls (Figure
S2A–D). Furthermore, inactivation of GSTA4 (HCT116DGSTA4)

Statistical Analysis
Data are expressed as means ± SEM from at least three
independent experiments. Student’s t-test or two-way ANOVA
was used for comparisons between groups using the GraphPad
Prism 8 software (GraphPad Software, CA, USA). P <0.05 was
considered statistically signiﬁcant.

RESULTS
Inactivation of GSTA4
To inactivate GSTA4 in HCT116 cells, we co-transfected
HCT116 cells with pLentiCRISPR-gRNA66 and
pLentiCRISPR-gRNA214 (Supplementary Table S1), which
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FIGURE 2 | Inactivation of GSTA4 inhibits proliferation. (A) CCK8 assay shows remarkably decreased viability of HCT116DGSTA4 cells compared to the parental
HCT116 cells. (B) Microphotographs of the clonogenic assay from triplicated wells. Upper panels, HCT116; Lower panels, HCT116DGSTA4. (C) Reduced number of
clones is seen for HCT116DGSTA4 cells compared to HCT116 cells. (D) Representative histograms for FACS analysis of EdU incorporation assay. (E) The proportion
of EdU-positive cells signiﬁcantly decreases in HCT116DGSTA4 compared to HCT116 cells. All data represent the mean ± SEM for three independent experiments. *P
<0.05; **P <0.01.

32.59 ± 1.56% to 13.24 ± 0.98%, P <0.01) for HCT116DGSTA4 cells
compared to a 19.22 ± 6.82% decrease (from 40.46 ± 2.40% to
30.53 ± 4.08%, P <0.05) for HCT116 cells (Figures 4A–C).
Comparably, treatment with oxaliplatin (0.5 µM) for 48 h also
resulted in a 56.77 ± 17.65% decreased proportion of EdUpositive cells (from 33.63 ± 4.04% to 10.01 ± 8.87%, P <0.01) for
HCT116DGSTA4 cells compared to a 11.77 ± 9.79% decrease (from
38.40 ± 5.39% to 18.86 ± 14.21%, P <0.05) for HCT116 cells
(Figures 4D–F). These results indicate that inactivation of
GSTA4 increases the sensitivity of colorectal cancer cells to
chemotherapeutic agents via inhibition of proliferation.

did not increase apoptosis compared with the parental HCT116
cells when treated with 5-FU (5 mM) and oxaliplatin (5 mM),
suggesting that loss of GSTA4 augmented chemotherapeutic
reduction of cell viability without affecting apoptosis.
We next examined cell proliferation using the EdU
incorporation assay following treatment with 5-FU and
oxaliplatin. In comparison with untreated controls, the
proportion of EdU-positive cells decreased for both HCT116
and HCT116 DGSTA4 cells after treatment with 5-FU and
oxaliplatin. Treatment with 5-FU (5 µM) for 48 h resulted in a
56.28 ± 4.93% decreased proportion of EdU-positive cells (from

Frontiers in Oncology | www.frontiersin.org
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FIGURE 3 | Inactivation of GSTA4 increases chemotherapeutic drug-induced cell killing. (A, B) CCK8 assay shows signiﬁcantly decreased viability for
HCT116DGSTA4 cells exposed to various doses of 5-FU (A) and oxaliplatin (B) compared to HCT116 cells. Data represent the mean ± SEM from three independent
experiments. **P <0.01; ns, not signiﬁcant.

signaling pathways including phosphoinositide 3 kinase (PI3K)
and MAPK. As shown in Figure 6, no remarkable change was
noted in the expression of AKT (a downstream kinase in the
PI3K signaling pathway) and p38 MAPK. However,
phosphorylated AKT (p-AKT) and phosphorylated p38 (pp38), the activated forms of AKT and p38, remarkably
decreased in HCT116DGSTA4 cells compared with HCT116
cells, indicating inhibition of AKT and p38 signaling pathways.
Additionally, treatment of HCT116 cells with 5-FU and
oxaliplatin slightly decreased p-AKT and p-p38 pathways in
HCT116 cells while being prone to increasing p-AKT and p-p38
in HCT116DGSTA4 cells. These results suggest that inactivation of
GSTA4 reduces proliferation by blocking PI3K/AKT and p38
MAPK signaling pathways and that activation of AKT and p38
pathways in HCT116 CRC cells occurs in a GSTA4dependent manner.

Inactivation of GSTA4 Promotes ROS
Production and DNA Damage
Many chemotherapeutic agents act as DNA damage inducers,
leading to cancer cell death. Inactivation of GSTs often induces
ROS production that causes DNA damage (29). However,
chemotherapeutic agents may also modulate GST expression and
ROS production (5, 30). Therefore, we measured ROS production in
HCT116DGSTA4 cells compared with that in HCT116 cells and
found that inactivation of GSTA4 increased ROS production in
untreated HCT116DGSTA4 cells in contrast to HCT116 cells.
Furthermore, ROS production also increased signiﬁcantly in
HCT116DGSTA4 cells treated with 5-FU and oxaliplatin compared
with HCT116 cells treated with the same drugs (Figure 5A). To
determine whether the inactivation of GSTA4 promotes DNA
damage, we analyzed phosphorylated H2AX (gH2AX), a hallmark
of double-stranded DNA breaks, by FACS analysis following
treatment with 5-FU and oxaliplatin. No signiﬁcant change was
seen in the proportion of gH2AX-positive cells between untreated
HCT116DGSTA4 and HCT116 cells (0.7 ± 0.82% vs 0.84 ± 0.98%, P =
0.859), suggesting that loss of GSTA4 has no effect on DNA damage
in unstressed cells. Following a 48-hour treatment with 5-FU, the
proportion of gH2AX-positive cells increased to 12.73 ± 1.06% and
4.23 ± 0.28% for HCT116DGSTA4 and HCT116 cells, respectively
(Figures 5B, C, P <0.01). In contrast, although the proportion of
gH2AX-positive cells increased for both HCT116DGSTA4 (1.67 ±
2.42%) and HCT116 cells (3.69 ± 6.00%) after treatment with
oxaliplatin for 48 h compared with untreated controls, no signiﬁcant
difference in the proportion of gH2AX-positive cells was seen
between HCT116DGSTA4 and HCT116 cells (Supplementary
Figures 3A, B, P = 0.618), indicating that the inactivation of
GSTA4 has limited effect on low-dose oxaliplatin-induced
crosslinking of DNA.

Inactivation of GSTA4 Inhibits Xenograft
Tumorigenesis
Finally, we investigated the effect of GSTA4-deﬁciency on
tumorigenesis using a xenograft tumor model. We injected
nude mice with 5 × 106 cells per side of the ﬂank and treated
them with saline, 5-FU, and oxaliplatin, respectively. For salinetreated mice, the average tumor size signiﬁcantly decreased for
HCT116DGSTA4-derived xenografts compared with HCT116derived xenografts (P <0.001), indicating reduced tumor
growth for GSTA4-deﬁcient HCT116 cells (Figure 7A). For
mice treated with 5-FU and oxaliplatin, the average tumor size
also signiﬁcantly decreased for xenografts derived from
H C T 1 1 6 D G S T A 4 c el l s c om p a r ed w i th H C T 1 1 6 c e ll s
(Figures 7B, C, P <0.05 for both 5-FU and oxaliplatin groups).
Of note, both 5-FU and oxaliplatin reduced tumor size in
HCT116-derived xenografts compared with saline control.
However, no signiﬁcant difference was found between 5-FU
and oxaliplatin (Figure 7D, P = 0.75). In contrast, for
HCT116DGSTA4-derived xenografts, 5-FU, but not oxaliplatin,
remarkably reduced tumor size compared to saline control
(Figure 7E, P <0.01 and P = 0.22 for 5-FU and oxaliplatin,

Inactivation of GSTA4 Reduces
Proliferation via Blocking AKT and p38
MAPK Signaling Pathways
To further investigate the mechanisms by which inactivation of
GSTA4 inhibits proliferation, we examined proliferative

Frontiers in Oncology | www.frontiersin.org
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FIGURE 4 | Inactivation of GSTA4 increases cell susceptibility to chemotherapeutics drugs. (A) Representative histograms for FACS analysis of the EdU
incorporation assay following treatment with PBS or 5-FU. (B) The percentage of EdU-positive cells signiﬁcantly decreases for HCT116DGSTA4 compared to HCT116
cells following 5-FU treatment. (C) Percent change of the EdU-positive cells for 5-FU-treated cells normalized to untreated cells. (D) Representative histograms for
FACS analysis of EdU incorporation assay following treatment with PBS or oxaliplatin. (E) The percentage of EdU-positive cells signiﬁcantly decreases for
HCT116DGSTA4 compared to HCT116 cells following oxaliplatin treatment. (F) Percent change of EdU-positive cells for oxaliplatin-treated cells normalized to
untreated cells. All data represent the mean ± SEM for three independent experiments. *P <0.05 and **P <0.01.

respectively). This is consistent with the ﬁndings that 5-FU, but
not oxaliplatin, at the tested doses, induced more gH2AX foci in
HCT116 DGSTA4 cells. These results indicate that GSTA4
promotes in vivo tumorigenesis and contributes
to chemoresistance.
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DISCUSSION
GSTA4 is overexpressed in the colon biopsies of human
colorectal cancer and the bacteria-induced murine CRC model
through activating oncogenic transcription factor activator
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FIGURE 5 | Inactivation of GSTA4 promotes ROS production and DNA damage. (A) ROS production signiﬁcantly increases for HCT116DGSTA4 compared to
HCT116 cells exposed to PBS, 5-FU, and oxaliplatin, respectively. (B) Representative histograms of FACS analysis for gH2AX. (C) No remarkable difference is noted
in the percentage of gH2AX for untreated HCT116DGSTA4 and HCT116 cells. The percentage of gH2AX signiﬁcantly increases for HCT116DGSTA4 compared to
HCT116 cells following treatment with 5-FU. All data represent the mean ± SEM for three independent experiments. **P <0.01; ns, not signiﬁcant.

that colorectal cancer cells expressed GSTA4 (6) and we show in
the current study that inactivation of GSTA4 in HCT116 cells
decreases proliferation via inhibition of PI3K/MAPK pathways,
supporting the tumor promotive role of GSTA4. Nonetheless, the
mechanisms of how GSTA4 regulates AKT and p38 activation
are still unknown. One potential process is that GSTA4, like
other GSTs, can directly interact with AKT and p38. Further
investigation is needed to conﬁrm this hypothesis in
HCT116DGSTA4 and HCT116 cells in which GSTA4 is silenced
by GSTA4-speciﬁc siRNA or shRNA.
4-HNE is a byproduct of lipid peroxidation that can alter
protein functions by forming 4-HNE-protein adducts, induce
DNA damage, and act as a signaling inducer (36, 37). 4-HNE
also induces apoptosis and inhibits proliferation by activating p21
and c-Myc in CRC cells (38). Because GSTA4 speciﬁcally
conjugates glutathione to 4-HNE and detoxiﬁes 4-HNE (37), we
expected that inactivation of GSTA4 was capable of increasing 4HNE-induced cell death, presumably via apoptosis caused by
accumulating 4-HNE. However, this study shows that
inactivation of GSTA4 has no effect on apoptosis in HCT116
cells. The survival rate indeed decreased signiﬁcantly for 4-HNEtreated HCT116DGSTA4 cells compared with the parental HCT116
cells. Nearly 20% of cells, however, still survived after 200 mM 4HNE treatment, indicating that alternative 4-HNE-detoxifying
mechanisms exist besides the GSTA4-mediated phase II
detoxifying pathway. These detoxifying mechanisms may be
phase I detoxifying enzymes such as aldehyde dehydrogenases,
alcohol dehydrogenases, aldo-keto reductase, and other enzymes

protein 1 (AP-1) (6). The impact of the overexpressed GSTA4 on
the CRC cells is, however, unclear. In this study, we investigated
the role of GSTA4 in CRC cells by deleting GSTA4 in HCT116
human colon cancer cells. Our results show that inactivation of
GSTA4 in HCT116 cells reduces cell proliferation and increases
chemotherapeutic drug sensitivity in vitro and in a xenograft
tumor model. Inactivation of GSTA4 increases intracellular ROS
production and blocks proliferative signaling pathways,
including AKT and p38 MAPK. These results show that
GSTA4 activation by AP-1 in CRC promotes tumor growth via
activation of proliferative signaling pathways.
Several GSTs regulate proliferation, tumorigenesis, tumor
progression, and metastasis (5, 31, 32). These GSTs can
directly interact with various signaling molecules to regulate
proliferation. For example, GSTO1-1 interacts with AKT and
MEK1/2, activating AKT signaling in human neuroblastoma
cells (33). Additionally, GSTP1 can regulate cell cycle
progression and proliferation through direct interaction with
JNK and TNF receptor-associated factor 2 (TRAF2) (32, 34).
Silencing of GSTP1 in pancreatic ductal adenocarcinoma cells
can affect both proliferation and apoptosis (7). While little is
known about the role of GSTA4 in cancer, particularly in
colorectal cancer, previous studies have demonstrated that
transfection of primary cell lines with human GSTA4expressing plasmids causes cellular transformation and
immortalization via upregulation of transforming growth
factor, cyclin-dependent kinase 2, and protein kinase C beta II
and downregulation of p53 (35). Our previous results showed
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FIGURE 6 | Inactivation of GSTA4 blocks AKT and MAPK signaling pathways. (A–C) Western blots show remarkable decrease of p-AKT in HCT116DGSTA4
compared to HCT116 cells treated with or without 5-FU or oxaliplatin after normalizing to b-actin. (D–F) Remarkably decreased p-p38 is seen in HCT116DGSTA4
compared to HCT116 cells treated with or without chemotherapeutic agents after normalizing to b-actin.

Interestingly, we have not seen increased proliferation or
apoptosis despite increased ROS in HCT116DGSTA4 cells.
Therefore, the slightly increased ROS may not be associated with
the blockage of proliferation in HCT116DGSTA4 cells, showing that
GSTA4 regulates proliferation by direct interaction with growth
signaling molecules such as AKT and p38.
Oxaliplatin and 5-FU are commonly used for the treatment of
early-stage CRC as adjuvant chemotherapy and the ﬁrst-line
chemotherapy for the metastatic CRC (42). Although both 5-FU
and oxaliplatin can cause DNA damage and, eventually, result in
cancer cell death, their mechanisms of action are different. 5-FU is
an anti-metabolite agent that inhibits thymidylate synthase and
incorporates its metabolites into DNA and RNA, leading to DNA
damage and cancer cell death (43). Oxaliplatin, on the other hand,
can form oxaliplatin-DNA adducts and crosslinks, leading to
apoptosis (44). Although both 5-FU and oxaliplatin can activate
gH2AX (45, 46), we found increased gH2AX in HCT116DGSTA4 cells
treated with 5-FU but not with oxaliplatin. This may be due to the
extremely low dosage of oxaliplatin (0.5 µM) that we have tested in
these experiments. Notably, previous studies have demonstrated

(39). Whether or not these enzymes could be compensatively upregulated by 4-HNE in GSTA4-deﬁcient cells is unclear. This is an
interesting topic that may merit further investigation but is beyond
the scope of this study.
The tumor microenvironment is enriched with ROS that have
multifaceted roles in cancer cell proliferation, apoptosis,
angiogenesis, and metastasis (29). GSTs, as anti-oxidant enzymes,
can eliminate ROS and protect cells against ROS-induced apoptosis
(5, 8). As such, we speculate that the deletion of GSTA4 in HCT116
cells also increases intracellular ROS. The results from this study
show that inactivation of GSTA4, as expected, increases ROS for
untreated cells and cells treated with 5-FU and oxaliplatin. Severely
increased ROS can induce apoptosis, but slightly increased ROS, on
the other hand, may promote proliferation and angiogenesis (40).
ROS regulates proliferation and apoptosis through various signaling
pathways, including AKT and MAPK (29, 40). ROS can also
promote CRC cell proliferation through the NOX1 pathway (41).
Notably, no increased apoptosis was seen in HCT116DGSTA4 cells
regardless of increased ROS, implying that inactivation of GSTA4
mildly increases ROS that might promote proliferation.
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FIGURE 7 | Inactivation of GSTA4 inhibits xenograft tumor growth and increases tumor susceptibility to chemotherapeutic drugs in vivo. (A–C) Signiﬁcantly
decreased tumor size is noted for HCT116DGSTA4-derived xenografts compared to HCT116-derived xenografts when exposed to saline (A), 5-FU (B), and oxaliplatin
(C), respectively. (D) Xenograft tumor size for HCT116 cells exposed to saline, 5-FU, and oxaliplatin. Both 5-FU and oxaliplatin reduce tumor size compared to saline
control (P <0.05 for both comparisons). No difference is seen between 5-FU and oxaliplatin (P = 0.75). (E) Xenograft tumor size for HCT116DGSTA4 cells exposed to
saline, 5-FU, and oxaliplatin. 5-FU (P <0.05), not oxaliplatin (P = 0.22), reduces tumor size compared to saline control. Data are expressed as means ± SEM. Twoway ANOVA is used for all comparisons. *P <0.05 and **P <0.01.

suggest that activation of GSTA4 in CRC cells promotes
tumorigenesis and contributes to chemoresistance, and that
GSTA4 is a potential therapeutic target for treating CRC.

that exposure of SW480 CRC cells to oxaliplatin at a dose of 10 µM,
which is 20-fold of the dose that we used to treat HCT116 cells in
this study, induced a remarkably low proportion of gH2AX-positive
cells (47). In congruence with the results of gH2AX expression, we
noted relatively low proportions of apoptotic cells in both HCT116
and HCT116DGSTA4 cells treated with 5-FU and oxaliplatin, which is
similar to the rates of apoptosis in HCT116 cells treated with these
drugs as reported by other investigators (48). Finally, the different
mechanisms of action for 5-FU and oxaliplatin may explain why 5FU, but not oxaliplatin, increases gH2AX caused by the inactivation
of GSTA4. Concomitantly, no signiﬁcantly decreased tumor size
was noted for HCT116DGSTA4-derived xenografts treated with
oxaliplatin compared to the untreated group (Figure 7E). This
was due to a signiﬁcant decrease in tumor size in the control group.
Previous studies have found that overexpression of GSTA2 protects
colon cancer cells against crosslinking agent-induced DNA damage
(49). Whether or not inactivation of GSTA4 increases oxaliplatininduced crosslinks is still unknown. Nevertheless, inactivation of
GSTA4 remarkably increases cell susceptibility to chemotherapeutic
agents in vitro and in the xenograft mouse model.
In conclusion, inactivation of GSTA4 decreases CRC cell
proliferation by blocking AKT and p38 MAPK signaling
pathways. Additionally, inactivation of GSTA4 increases
intracellular ROS and cancer cell susceptibility to the
chemotherapeutic agents, 5-FU and oxaliplatin. These results
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